Cargando…
Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides
Mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL), is characterized by malignant CD4+ skin-homing T-cells that drive formation of cutaneous patches, plaques, and/or tumors. MF’s known immunogenicity makes it an ideal candidate for local immunotherapy. Recombinant human...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
YJBM
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087069/ https://www.ncbi.nlm.nih.gov/pubmed/32226334 |
_version_ | 1783509259911168000 |
---|---|
author | Hu, Jamie Katy Carlson, Kacie Girardi, Michael |
author_facet | Hu, Jamie Katy Carlson, Kacie Girardi, Michael |
author_sort | Hu, Jamie Katy |
collection | PubMed |
description | Mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL), is characterized by malignant CD4+ skin-homing T-cells that drive formation of cutaneous patches, plaques, and/or tumors. MF’s known immunogenicity makes it an ideal candidate for local immunotherapy. Recombinant human leukocyte interferon-α2 (rIFN-α2) has well-established immunomodulatory, antiproliferative, and antitumor effects; and relatively low levels of endogenous IFN-α have been observed within MF lesions. As a systemic therapy delivered via subcutaneous (SC) or intramuscular (IM) injection, rIFN-α2 has previously shown efficacy against MF. Due to high levels of toxicity associated with the systemic dosing required for improvement of disease, rIFN-α2 has had limited use in the treatment of MF. For these reasons, we sought to deliver rIFN-2 as a local immunotherapy, and herein describe two cases of MF successfully managed with intralesional injections of low-dose rIFN-α2. With limited reporting in the medical literature, intralesional injection of rIFN-α2 has shown efficacy, but with high frequency of associated systemic side effects. Towards a better tolerated, localized immunotherapy, we initiated treatment in two MF patients with low dose (0.5 MU) rIFN-α2 per injection that led to marked responses, and subsequent dosing to 1.0 MU ultimately led to complete resolution of the treated lesions without the generalized side effects observed with systemic administration of rIFN-α2. These cases suggest that low-dose intralesional rIFN-α2 may be an efficacious and well-tolerated local immunotherapy for early stage MF, providing a therapeutic option for the management of chronic, recalcitrant lesions. |
format | Online Article Text |
id | pubmed-7087069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | YJBM |
record_format | MEDLINE/PubMed |
spelling | pubmed-70870692020-03-27 Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides Hu, Jamie Katy Carlson, Kacie Girardi, Michael Yale J Biol Med Case Report Mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL), is characterized by malignant CD4+ skin-homing T-cells that drive formation of cutaneous patches, plaques, and/or tumors. MF’s known immunogenicity makes it an ideal candidate for local immunotherapy. Recombinant human leukocyte interferon-α2 (rIFN-α2) has well-established immunomodulatory, antiproliferative, and antitumor effects; and relatively low levels of endogenous IFN-α have been observed within MF lesions. As a systemic therapy delivered via subcutaneous (SC) or intramuscular (IM) injection, rIFN-α2 has previously shown efficacy against MF. Due to high levels of toxicity associated with the systemic dosing required for improvement of disease, rIFN-α2 has had limited use in the treatment of MF. For these reasons, we sought to deliver rIFN-2 as a local immunotherapy, and herein describe two cases of MF successfully managed with intralesional injections of low-dose rIFN-α2. With limited reporting in the medical literature, intralesional injection of rIFN-α2 has shown efficacy, but with high frequency of associated systemic side effects. Towards a better tolerated, localized immunotherapy, we initiated treatment in two MF patients with low dose (0.5 MU) rIFN-α2 per injection that led to marked responses, and subsequent dosing to 1.0 MU ultimately led to complete resolution of the treated lesions without the generalized side effects observed with systemic administration of rIFN-α2. These cases suggest that low-dose intralesional rIFN-α2 may be an efficacious and well-tolerated local immunotherapy for early stage MF, providing a therapeutic option for the management of chronic, recalcitrant lesions. YJBM 2020-03-27 /pmc/articles/PMC7087069/ /pubmed/32226334 Text en Copyright ©2020, Yale Journal of Biology and Medicine https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons CC BY-NC license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use the material for commercial purposes. |
spellingShingle | Case Report Hu, Jamie Katy Carlson, Kacie Girardi, Michael Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides |
title | Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides |
title_full | Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides |
title_fullStr | Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides |
title_full_unstemmed | Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides |
title_short | Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides |
title_sort | low-dose intralesional recombinant interferon-α2b in the treatment of mycosis fungoides |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087069/ https://www.ncbi.nlm.nih.gov/pubmed/32226334 |
work_keys_str_mv | AT hujamiekaty lowdoseintralesionalrecombinantinterferona2binthetreatmentofmycosisfungoides AT carlsonkacie lowdoseintralesionalrecombinantinterferona2binthetreatmentofmycosisfungoides AT girardimichael lowdoseintralesionalrecombinantinterferona2binthetreatmentofmycosisfungoides |